You are here

Development of Alkontrol herbal for Treating Alcohol Abuse

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R42AA022577-01A1
Agency Tracking Number: R42AA022577
Amount: $154,747.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NIAAA
Solicitation Number: PA13-235
Solicitation Year: 2014
Award Year: 2016
Award Start Date (Proposal Award Date): 2016-09-20
Award End Date (Contract End Date): 2017-08-31
Small Business Information
Burlington, MA 01803-4990
United States
DUNS: 926458290
HUBZone Owned: No
Woman Owned: Yes
Socially and Economically Disadvantaged: No
Principal Investigator
 (781) 272-6888
Business Contact
Phone: (781) 272-6888
Research Institution

DESCRIPTION provided by applicant This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia International Inc NPI and McLean Hospital to initiate steps toward commercializing a isoflavone botanical product for treating alcoholism Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal alcohol syndrome fatal motor crashes accidents and homicides On college campuses alone alcohol use results annually in almost deaths sexual assaults injuries and assaults For most problematic drinking and its associated morbidity will not be brought to the attention of Primary Care Professionals and so many go without treatment This is precisely where an OTC herbal product could have the greatest impact An extract of kudzu Pueraria lobata has been patented by McLean Hospital and licensed it to NPI under the name Alkontrol herbal Over the past years our team has extensively studied this kudzu extract and demonstrated its safety and efficacy in healthy control subjects as well as in heavy binge drinkers The reason for pursuing the STTR mechanism is two fold while NPI has been able to produce enough product for our modest clinical studies they are not in a position to ramp up full production in order to support larger scale clinical trials and we have conducted and published studies in human subjects but we have yet to conduct a study in heavy drinkers who are alcohol dependent and are treatment seeking Thus there is a significant need for this clinical trial to demonstrate efficacy in this important population The reason for the Fast Track approach is that we have already developed product licensed it to NPI and have the backbone of a commercialization plan but need fiscal support to develop the processes needed to increase production of enough standardized product to support not only the clinical trial but to be able to meet the needs once the commercialization plan is implemented Thus Phase I will be focused on providing NPI with the infrastructure to scale up production of standardized high quality Alkontrol herbal while the
clinical trial will be the major milestone of Phase II Collectively successful completion of thes two phases will pave the way for the commercialization of Alkontrol herbal Key milestones for Phase I include procure and authenticate Pueraria lobata from our source in China perform GMP extraction and precipitation develop independent QC analytical protocols optimize ratio of isoflavones and finalize submission of an IND for FDA approved labeling and IRB applications Phase II milestones include scale up production of Alkontrol herbal isolate puerarin for standardization develop a urinary biomarker for medication adherence and conduct proof of concept clinical trial in treatment seeking alcohol dependent individuals

PUBLIC HEALTH RELEVANCE The proposed STTR project represents a collaboration between the small business Natural Pharmacia International Inc and McLean Hospital to ramp up production of Alkontrol herbal and conduct a clinical trial in treatment seeking alcohol dependent heavy drinking individuals

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government